美股
Lead report
Immunovant Q1 FY2027 Earnings Preview: IMVT-1402 Progress and Cash Runway in Focus
Immunovant is set to report Q1 FY2027 results, with investors eyeing IMVT-1402 clinical updates, batoclimab's fate, and cash burn. Pipeline catalysts and valuation risks are analyzed.
